Relapse After Second-Line Therapy in Follicular Lymphoma
Relapse After Second-Line Therapy in Follicular Lymphoma
Case:A 72-Year-Old Woman With Relapsed Follicular Lymphoma
H & P:
- A 75-year-old woman presented with severe fatigue and weight loss
- Was diagnosed with inguinal contiguous stage II follicular lymphoma (FL) 4.5 years ago; completed BR and achieved PR that persisted for almost 4 years
- Started treatment with R-CHOP for extensive mediastinal FL 6 months ago; had achieved PR by 3 months before symptoms returned
- PMH: Type 2 diabetes X 10 years, controlled on basal insulin and SGLT2 inhibitor
- PE: Swelling present in right axillary lymph nodes; not tender to touch; no crackles or rales in lungs; no history of pneumonia; has received flu and PPV23 vaccination
- ECOG performance status: 1
- Biopsy showed grade 2 FL without transformation
- Labs:
- eGFR = 72 mL/min/1.732
- AST/ALT: within normal range
- ANL: 1350 /mm3
- Platelets: 100,00 /µL
- Hemoglobin: 10 g/dL
- LDH: 275 U/L
- Imaging: PET/CT revealed axillary lymphadenopathy, with largest mass 7.2 cm
- She was started on idelalisib 150 mg b.i.d.
- After 10 days, she called with concerns about diarrhea, which she has been experiencing on average 4 times daily for the past few days
Does Odronextamab Show Hope in FL and DLBCL Despite Regulatory Hurdles?
November 5th 2024Despite regulatory challenges from the FDA, odronextamab has received European approval for the treatment of patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma following 2 prior treatments.
Read More
Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets Primary End Point
August 16th 2024The phase 3 inMIND trial evaluating tafasitamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma showed promising progression-free survival findings, according to topline results.
Read More
Behind the FDA Approval of Zanubrutinib and Obinutuzumab in Follicular Lymphoma
March 8th 2024Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.
Read More
